PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) announced that its management team will participate in the H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 8–10, 2025, in New York City.
President and CEO Will Chou, M.D., will deliver a company presentation providing an overview of Passage Bio’s clinical programs and strategic priorities. In addition, company executives will conduct one-on-one meetings with investors during the conference.
A video webcast of the presentation will be available to registered attendees beginning Friday, September 5, 2025, at 7:00 a.m. ET, with an archived replay accessible for 30 days.
Passage Bio is a clinical-stage genetic medicines company focused on developing one-time therapies for neurodegenerative diseases. Its lead candidate, PBFT02, is designed to elevate progranulin levels to restore lysosomal function and slow disease progression in conditions such as frontotemporal dementia.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.